Filing Flows

Filing Flows › Amphastar Pharmaceuticals (AMPH) › Next earnings date

Amphastar Pharmaceuticals (AMPH) earnings: beat the estimate

Amphastar Pharmaceuticals (AMPH) reported on Nov 5, 2026 and beat the EPS estimate: $1.14 against $0.86 (+32.8%). Revenue was $208M for Q3 2026, +8% year over year. It beat the EPS estimate in 60% of the quarters on record.

Last result+32.8% vs estimate
Beat rate60%

The last report

Amphastar Pharmaceuticals reported revenue of $208M for the third quarter 2026 (+8% Y/Y), net earnings $37.8M. How it makes money → · Every quarter →

Amphastar Pharmaceuticals: EPS against the estimate, last 5 reportsAmphastar Pharmaceuticals: EPS against the estimate, last 5 reportsEstimateReported$0.83$0.93Nov 25$0.92$0.73Feb 26$0.71$0.42May 26$0.61$0.91Aug 26$0.86$1.14Nov 26
Latest (Nov 26): Estimate $0.86, Reported $1.14.
AMPH: the stock's move on each reportAMPH: the stock's move on each reportAug 6, 2026+2.7%May 7, 2026-20.5%Feb 26, 2026-27.7%Nov 6, 2025-5.1%

Amphastar Pharmaceuticals' latest quarter

Amphastar Pharmaceuticals, Q3 2026: revenue $208M (+8% year over year), operating margin 24.5%, net earnings $37.8M, operating cash flow $43.3M. The chart follows the revenue to costs, profit and cash.

Questions

Did Amphastar Pharmaceuticals beat earnings?

Amphastar Pharmaceuticals (AMPH) reported on Nov 5, 2026 and beat the EPS estimate: $1.14 against $0.86 (+32.8%).

When does AMPH report earnings?

The next date is not set yet.

Does Amphastar Pharmaceuticals usually beat earnings?

It beat the consensus EPS estimate in 60% of the quarters on record.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.